WO2010001258A3 - Inhibition of tumour growth and metastases - Google Patents

Inhibition of tumour growth and metastases Download PDF

Info

Publication number
WO2010001258A3
WO2010001258A3 PCT/IB2009/006592 IB2009006592W WO2010001258A3 WO 2010001258 A3 WO2010001258 A3 WO 2010001258A3 IB 2009006592 W IB2009006592 W IB 2009006592W WO 2010001258 A3 WO2010001258 A3 WO 2010001258A3
Authority
WO
WIPO (PCT)
Prior art keywords
metastases
inhibition
solid cancers
tumour growth
compound
Prior art date
Application number
PCT/IB2009/006592
Other languages
French (fr)
Other versions
WO2010001258A2 (en
Inventor
Bohdan Wasylyk
Jack Schalken
Gabri Van Der Pluijm
Original Assignee
Centre National De La Recherche Scientifique
Universite De Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique, Universite De Strasbourg filed Critical Centre National De La Recherche Scientifique
Publication of WO2010001258A2 publication Critical patent/WO2010001258A2/en
Publication of WO2010001258A3 publication Critical patent/WO2010001258A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

The instant invention relates to compounds of formula 1 and their applications as an anti-cancer agent and/or as an angiogenesis inhibitor in mammals, preferably in humans; the instant invention also includes a method of treatment of metastases of prostate cancers using said compound and also a method of treatment of conditions in which angiogenesis must be inhibited. Said compound of formula 1 wherein R1 is a C1-C6 alkyl group, substituted or not, linear or branched and R2 represents a halogen atom, is useful for treating solid cancers or preventing metastases of solid cancers, said solid cancers being selected in the group consisting of lung cancer, glioma and prostate cancer.
PCT/IB2009/006592 2008-06-30 2009-06-26 Inhibition of tumour growth and metastases WO2010001258A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7700408P 2008-06-30 2008-06-30
US61/077,004 2008-06-30

Publications (2)

Publication Number Publication Date
WO2010001258A2 WO2010001258A2 (en) 2010-01-07
WO2010001258A3 true WO2010001258A3 (en) 2010-02-25

Family

ID=41136725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/006592 WO2010001258A2 (en) 2008-06-30 2009-06-26 Inhibition of tumour growth and metastases

Country Status (1)

Country Link
WO (1) WO2010001258A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289365B2 (en) * 2011-10-24 2016-03-22 Avon Products, Inc. Compositions and methods for stimulating collagen synthesis in the skin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1202065A1 (en) * 2000-10-25 2002-05-02 Aventis Pharma S.A. Net, a transcription factor of the TCF family, as regulator of angiogenic expression.
WO2004078732A1 (en) * 2003-01-28 2004-09-16 Aventis Pharma S.A. N-aryl heteroaromatic products, compositions containing same and use thereof
CN1969853A (en) * 2006-11-30 2007-05-30 四川大学华西医院 Use of N-aryl heterocyclics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1202065A1 (en) * 2000-10-25 2002-05-02 Aventis Pharma S.A. Net, a transcription factor of the TCF family, as regulator of angiogenic expression.
WO2004078732A1 (en) * 2003-01-28 2004-09-16 Aventis Pharma S.A. N-aryl heteroaromatic products, compositions containing same and use thereof
CN1969853A (en) * 2006-11-30 2007-05-30 四川大学华西医院 Use of N-aryl heterocyclics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 June 2007 (2007-06-04), ZHENG, HONG: "Application of N-aryl heterocycle compound for inhibiting tumor metastasis", XP002555395, retrieved from STN Database accession no. 2007:597797 *
WASYLYK, CHRISTINE ET AL: "Inhibition of the Ras-Net (Elk-3) Pathway by a Novel Pyrazole that Affects Microtubules", 1 March 2008, CANCER RESEARCH , 68(5), 1275-1283 CODEN: CNREA8; ISSN: 0008-5472, XP002555397 *

Also Published As

Publication number Publication date
WO2010001258A2 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
GEP20146138B (en) Method for treating androgen receptor positive cancers
TN2009000034A1 (en) Smac peptidomimetics useful as iap inhibitors
HK1093159A1 (en) Monocyclic heterocycles as kinase inhibitors
NZ595206A (en) Prodrug forms of kinase inhibitors and their use in therapy
TN2009000255A1 (en) Quinazolines for pdk1 inhibition
MX2009000657A (en) Compositions and methods for the treatment of mucositis.
WO2007085895A3 (en) Fap inhibitors
MX2009004699A (en) Pyridinone compounds.
EP2170337A4 (en) Novel triazolopyridazines
MX2010003365A (en) Thiazol derivatives for treating cancer.
MX2012001420A (en) Pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors.
WO2009047298A3 (en) Dimers of harmol or of its derivatives and uses thereof
PH12015500008B1 (en) Dimethyl-benzoic acid compounds
WO2009121033A3 (en) Substituted nitrogen heterocycles and synthesis and uses thereof
NZ602368A (en) Iap bir domain binding compounds
WO2010021934A3 (en) Azaindole inhibitors of iap
MX2009005649A (en) Treatment for multiple myeloma.
SG11201903875QA (en) Selective inhibitor of exon 20 insertion mutant egfr
WO2009156041A3 (en) Thiazolyl piperdine derivatives
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
MX2021003843A (en) Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer.
WO2008142550A8 (en) Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
NZ611169A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
WO2011086412A3 (en) Imidazolone-chalcone derivatives as potential anticancer agent and process for the preparation thereof
EP3345597A3 (en) Pkc delta inhibitors for use as therapeutics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09772918

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09772918

Country of ref document: EP

Kind code of ref document: A2